Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Hong

Showing results (151-160 of 272) with videos related to

Pageof 28
Sort By:
Scientific Reports|February 22, 2020
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignanciesYudong Wang, Filip Janku, Sarina Piha-Paul, et al.
British Journal of Cancer|March 6, 2021
Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignanciesShuyang Yao, Filip Janku, Vivek Subbiah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2013
Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trialAna M Gonzalez-Angulo, Funda Meric-Bernstam, Sant Chawla, et al.
Frontiers in Chemistry|June 10, 2021
Chemical Composition, Antimicrobial and Insecticidal Activities of Essential Oils of Discarded Perfume Lemon and Leaves (<i>Citrus Limon</i> (L.) Burm. F.) as Possible Sources of Functional Botanical AgentsPanpan Wu, Xiaowen Tang, Rongchao Jian, et al.
Nature Medicine|July 27, 2023
Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim resultsRaffit Hassan, Marcus Butler, Roisin E O'Cearbhaill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2009
Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumorsRoy S Herbst, David Hong, Linnea Chap, et al.
Gynecologic Oncology Research and Practice|May 28, 2016
Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experienceSiqing Fu, Naiyi Shi, Jennifer Wheler, et al.
Targeted Oncology|December 2, 2022
Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid TumorsChristian Kollmannsberger, Herbert Hurwitz, Lyudmila Bazhenova, et al.
AJNR. American Journal of Neuroradiology|February 20, 2026
Large Language Models for Accurate Medical Chart Abstraction: Enabling Scalable and Secure AI Deployment in StrokeZhusi Zhong, Carl M Porto, David Hong, et al.
The American Journal of Cardiology|February 16, 2019
Targeted Cancer Therapies With Pericardial Effusions Requiring Pericardiocentesis Focusing on Immune Checkpoint InhibitorsNicolas Palaskas, Jacob Morgan, Tina Daigle, et al.
Pageof 28

Showing results (151-160 of 272) with videos related to

Sort By:
Pageof 28
Scientific Reports|February 22, 2020
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignanciesYudong Wang, Filip Janku, Sarina Piha-Paul, et al.
British Journal of Cancer|March 6, 2021
Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignanciesShuyang Yao, Filip Janku, Vivek Subbiah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2013
Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trialAna M Gonzalez-Angulo, Funda Meric-Bernstam, Sant Chawla, et al.
Frontiers in Chemistry|June 10, 2021
Chemical Composition, Antimicrobial and Insecticidal Activities of Essential Oils of Discarded Perfume Lemon and Leaves (<i>Citrus Limon</i> (L.) Burm. F.) as Possible Sources of Functional Botanical AgentsPanpan Wu, Xiaowen Tang, Rongchao Jian, et al.
Nature Medicine|July 27, 2023
Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim resultsRaffit Hassan, Marcus Butler, Roisin E O'Cearbhaill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2009
Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumorsRoy S Herbst, David Hong, Linnea Chap, et al.
Gynecologic Oncology Research and Practice|May 28, 2016
Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experienceSiqing Fu, Naiyi Shi, Jennifer Wheler, et al.
Targeted Oncology|December 2, 2022
Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid TumorsChristian Kollmannsberger, Herbert Hurwitz, Lyudmila Bazhenova, et al.
AJNR. American Journal of Neuroradiology|February 20, 2026
Large Language Models for Accurate Medical Chart Abstraction: Enabling Scalable and Secure AI Deployment in StrokeZhusi Zhong, Carl M Porto, David Hong, et al.
The American Journal of Cardiology|February 16, 2019
Targeted Cancer Therapies With Pericardial Effusions Requiring Pericardiocentesis Focusing on Immune Checkpoint InhibitorsNicolas Palaskas, Jacob Morgan, Tina Daigle, et al.
Pageof 28